OA19038A - Method for highly expressing recombinant protein of engineering bacteria and use thereof. - Google Patents
Method for highly expressing recombinant protein of engineering bacteria and use thereof. Download PDFInfo
- Publication number
- OA19038A OA19038A OA1201400217 OA19038A OA 19038 A OA19038 A OA 19038A OA 1201400217 OA1201400217 OA 1201400217 OA 19038 A OA19038 A OA 19038A
- Authority
- OA
- OAPI
- Prior art keywords
- bacteria
- protein
- pmc
- recombinant protein
- medium
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 75
- 108010033725 Recombinant Proteins Proteins 0.000 title claims abstract description 37
- 102000007312 Recombinant Proteins Human genes 0.000 title claims abstract description 37
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 45
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 45
- 241000588724 Escherichia coli Species 0.000 claims abstract description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 48
- 239000011780 sodium chloride Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 24
- 239000001888 Peptone Substances 0.000 claims description 17
- 108010080698 Peptones Proteins 0.000 claims description 17
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 17
- 235000019319 peptone Nutrition 0.000 claims description 17
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 16
- 239000004327 boric acid Substances 0.000 claims description 16
- 238000005342 ion exchange Methods 0.000 claims description 15
- 239000001110 calcium chloride Substances 0.000 claims description 14
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 239000007863 gel particle Substances 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 13
- 239000007836 KH2PO4 Substances 0.000 claims description 11
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- GNSKLFRGEWLPPA-UHFFFAOYSA-M Monopotassium phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 6
- 230000035939 shock Effects 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 5
- 238000011068 load Methods 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl β-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 4
- 206010053317 Hydrophobia Diseases 0.000 claims description 3
- 238000001742 protein purification Methods 0.000 abstract description 4
- 239000006228 supernatant Substances 0.000 abstract description 3
- 238000011031 large scale production Methods 0.000 abstract 1
- 239000002609 media Substances 0.000 description 47
- 230000003115 biocidal Effects 0.000 description 17
- 239000000499 gel Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 13
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 13
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 13
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 13
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 13
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 13
- 239000003242 anti bacterial agent Substances 0.000 description 13
- 229940079866 intestinal antibiotics Drugs 0.000 description 13
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 230000000844 anti-bacterial Effects 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 230000001580 bacterial Effects 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229960002385 Streptomycin Sulfate Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N Adenosine monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 229950006790 Adenosine phosphate Drugs 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 229960001931 Ampicillin Sodium Drugs 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037240 fusion proteins Human genes 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N Oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 206010041925 Staphylococcal infection Diseases 0.000 description 2
- 229940076185 Staphylococcus aureus Drugs 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 230000000941 anti-staphylcoccal Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960001019 oxacillin Drugs 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- QOCUBLCWSHICQY-WNQIDUERSA-N (2S)-2-amino-3-hydroxypropanoic acid;phenylmethanesulfonyl fluoride Chemical compound OC[C@H](N)C(O)=O.FS(=O)(=O)CC1=CC=CC=C1 QOCUBLCWSHICQY-WNQIDUERSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229940032049 Enterococcus faecalis Drugs 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 229940052778 Neisseria meningitidis Drugs 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101700015701 SPI Proteins 0.000 description 1
- 235000015076 Shorea robusta Nutrition 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 Vancomycin Drugs 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 230000003385 bacteriostatic Effects 0.000 description 1
- 239000007474 bm medium Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 201000009906 meningitis Diseases 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 230000000630 rising Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
Provided are methods for highly expressing a recombinant protein of engineering bacteria and the use thereof. The method comprises the following steps: (1) engineering bacteria of Escherichia coli with pET system are transfected with recombinant mutated plasmid to obtain positive monoclonal colonies; (2) the positive monoclonal colonies are enriched to obtain a seed bacteria solution, and the seed bacteria solution is induced to enrichment and growth in a large amount; and (3) the bacteria supernatant containing the recombinant protein as the expression target is separated, and then the recombinant protein in the bacteria supernatant is extracted and purified. The method is characterized in that the engineering bacteria of Escherichia coli with pET system are E.coliB834 (DE3). The components of the mass enrichment medium and the protein purification steps are also optimized such that a significant improvement in the yield and purity of the protein is achieved and the method is suitable for applying to the largescale production of recombinant protein expressed by the engineering bacteria of Escherichia coli.
Description
METHOD FOR HIGHLY EXPRESSING RECOMBINANT PROTEIN OF ENGINEERING BACTERIA AND USE THEREOF
TECHNICAL FIELD
The invention relates to biotechnology, especially to a method for highly expressing a recombinant protein of engineering bacteria and the use thereof.
............BACKGROUND OF INVENTION ...... ........
In earlier studies, the inventor conducted créative experiments and obtained a sériés of new recombinant peptides with Colicin'as attack point, which operationally connects a polypeptide (natural or artificial design) with identification and binding ability to target cells. For example, the new antibiotic PMC-AM1 disclosed in patent No.
ZL200910092128.4, named “Novel antibiotic comprising an antibody mimetic, its préparation and uses thereof’, shows a broad-spectrum antibiotic property and has stronger antibacterial activity on Neisseria meningitidis, Multidrug-resistance Pseudomonas aeruginosa, Vancomycin-resistant Enterococcus faecalis or Methicillin-resistant Staphylococcus aweu compared to the known antibiotics. The inventor’s another invention in title “A novel antibiotic, its nucléotide sequence, methods of construction and uses thereof’, with CN patent No.ZL200910157564.5, disclosed a sériés of new anti-staphylococcus antibiotics, such as PMC-SA1 ,
PMC-SA2> PMC-SA3> PMC-SA4> PMC-SE as well as PMC-PA. In vivo and vitro experiments, these antibiotics showed better targetîng ability and stronger antibacterial ------actLV.ity_than-currenUantibiotics,-anti.fungal-antibiotic-and-chemotherapcut-iGS-drug-s;-----—
Additionally compared with current antibiotics, these new antibiotics showed incomparable biological security and anti drug-resistance characteristic.
The foresaid novel antibiotics as a whole are a kind of water-soluble proteins with 600 amino acid residues, but in which there is a hydrophobie domain with 40 amino acid residues near carboxyl terminal. Compared to préparation of other water-soluble i
proteins with one fold structure, there is more difficult in assembling and expressing of the novel antibiotics, which inevitably affects protein yield. It is necessary to improve current expression process to achieve high yield and priority of the novel antibiotics. It will make sense for bringing the novel antibiotics into actual clinical application and 5 practice..
........Summary of invention .......................... ......................
------AGeording-to-the-peptide-structure-and-ehar-aeteristies-of-the-new-antibioties-diselosedin the current patent application, the present disclosure provides for a method for highly 10 expressing recombinant protein of engineering bacteria.
In one aspect, the present disclosure provides for A method for highly expressing recombinant protein of engineering bacteria, wherein the end with hydrophilicity of the recombinant protein is colicin polypeptide and the other end with hydrophobie nature is polypeptide of target moiety which is capable of binding target, the method comprising:
(1) transfecting recombinant plasmid of expressing the recombinant protein into E. coli engineering bacteria with pET system to obtain positive monoclonal colonies, (2) producing seed bacteria solution of the positive monoclonal colonies, and inducing protein expression and enlargement culturing of the seed bacteria solution; the -----supematant—of—the—enlargement— eultured—solution—eontains—expressed—reeombinant- protein, (3) extracting and purifying the recombinant protein from the supematant, wherein the
E. coli engineering bacteria with pET system is E.coliB834 (DE3).
In some exemplary embodiments, the enlargement culturing medium used for said inducing enriching growth of the seed bacteria solution has water as solvent and comprises following components: NaCl 6,0~6.7g/L, peptone 25.0g/L, yeast powder 7.5g/L, glucose 0.6~2.0g/L, Na2HPO47H2O 6.8~18.3g/L, KH2PO4 3.0~4.3g/L,
NH4Cl 1.0~l .4g/L, MgSO4 0.2~0.4g/L, CaCl20.01g/L, méthionine 0~40mg/L.
In a préférable exemplary embodiment, said enlargement culturing medium has water ....... as solvent and comprises following components: NaCl 6.0g/L, peptone 25.Og/L, yeast -----powder-7τ5g/L·Γglueose-270g/¾-Na2HPΘ4-7Ή2Θ-6Γ8g/L·ΓIζH2PΘ4-3τ0g/L·ΓNΉ-4θl-hΘg/L·,--MgSO4 0.2g/L, CaCl20.01g/L, méthionine 0~40mg/L.
In some exemplary embodiments, said enlargement culturing of the seed bacteria solution comprises following steps: the seed bacteria liquid was added into a container and started growth for 2 to 3 hours at 30°C, when the OD value reached 0.4-0.6, the seed bacteria solution was conducted heat shock at 42 °C for 30 minutes, and then cooled down to 37°C and kept growth for 1.5 to 2 hours before being collected.
In some exemplary embodiments, wherein in conducting heat shocks the IPTG with the final density 0.5mmol/L was added into said enlargement-culturing medium.
In some exemplary embodiments, said extracting and purifying the recombinant protein from the supematant was by CM ion exchange column, and the loading quantity of the
-----supematant dépends on the ratio value which is 2.5mg/ml between the weight of the----recombinant protein in the supematant and the volume of Gel particles used in the CM ion exchange column.
In some exemplary embodiments, the eluent solution used for said extracting and purifying in CM ion exchange column is boric acid buffer solution with 0.2mol/L NaCl.
In most exemplary embodiments, said recombinant plasmid of expressing the recombinant protein is selected from the group consisted ofpBHC-SAl > pBHC-SA2 > pBHC-SA3 pBHC-SA4> pBHC-SE, pBHC-PA and pBHC-PorAl.
fri an further aspect, the présent disclosure provides for the applications of any foresaid methods in preparing the recombinant peptides PMC- SA1, PMC-SA2, PMC-SA3,
........PMC-SA4, PMC -SE, PMC-PA or PMC-AM.....................................
In another aspect, the présent disclosure provides for a medium used for E. coli 10 engineering bacteria with pET system, the medium has water as solvent and comprises following components: NaCl 6.0~6.7g/L, peptone 25.0g/L, yeast powder 7.5g/L, glucose 0.6~2.0g/L, Na2HPO4-7H2O 6.8~18.3g/L, KH2PO4 3.0~4.3g/L, NH4C1 1.0-1.4g/L, MgSO4 0.2~0.4g/L, CaCl20.01g/L, méthionine 0~40mg/L.
In some exemplary embodiments, said E. coli engineering bacteria with pET system is 15 E. coli B834 (DE3), and the medium has water as solvent and comprises following components: NaCl 6.0g/L, peptone 25.0g/L, yeast powder 7.5g/L, glucose 2.0g/L, Na2HPO4-7H2O6.8g/L, KH2PO4 3.0g/L, NH4C11.0g/L, MgSO40.2g/L, CaCl20.01g/L, méthionine 0~40mg/L.
The pET expression system provided by Novagen Company is a common system for cloning and expressing recombinant proteins in Escherichia coli. In this invention, a ------séries of BL-21 (DE3) cells are transcctcd with recombinant mutated plasmid disclosed in former patents and produced a higher protein expression yieid than the TGI cells does in this invention. By experimental data, we found that B834 (DE3) , which is parent strain of BL-21 (DE3 ) , has a more idéal expression productivity than BL-21 (DE3) . The experimental data showed that the B834 (DE3) has dozens time of protein expression productivity than TGI system does.
Medium is used for providing required carbon source, nitrogen source and inorganic salts for bacterium growth and multiplication. In présent a medium with capability of improving the expression productivity of target protein is provided in présent invention, which has a optimum formula for engineering bacteria fermentation. In this invention, the medium, named FB-M9 compound medium has a increased carbon source and nitrogen source and MgSO4, CaCl2 as well as some spécial amino acids that are ........required in growth of engineering bacteria with pET system. The medium moderatcly ------improved-engineering-baGteria-reproduction-speGd-and-protein-exprGssion-ratc^-And----material cost of the improved medium is relatively low, which provides larger research space and higher development value for enlargement production in the future.
According to guide of the product manual, the carrying rate of CM ion gel particles used in purification system in this invention could not reach the idéal standard described in the product manual, which limits the recovery rate of target protein. In 15 présent invention, the recovery rate has been significantly improved by the means of reducing loading quantity of sample while moderately increasing the gel volume, etc. The resuit also reflected that it is necessary to find or develop a kind of ion exchange gel with more efficient for large-scale industrial production of the target protein. In addition, the recombinant proteins has fewer impurities owing to eluent with optimized 20 concentration used in the ion exchange steps of this invention.
-----In-summaryH&is-mvention-provides-a-variet-y-ofioptional-more-optimÎzed-method-of---expressing E. coli engineering bacteria recombinant proteins by the means of choosing engineering strains, optimizîng the composition of medium, improving the purification and recovery rate, etc. This also provides a possible research direction and technical route for finally finding optimal procedure of high-efficiently expressing fusion protein needed. Compared with the original expressing system disclosed in former patents, the expressing system developed by présent invention has improved the expressing production of fusion protein dozens of times, and provided a bénéficiai basis of theory and practice for the subséquent large-scale industrial production.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows the conductance value of eluent in the protein elution process with different volume gel column.
.................a. The elution process of protein with 150ml CM gel column. b. the elution ------process of protein with 600ml CM gel column.------------------------------------The curve signified by two arrows in the figure represent the conductance value of 10 the eluent. The area indicated by the arrows is a conductance peak caused by the loss of the sample PMC-SA in loading process. The area of the conductance peak caused by the loss of the sample PMC-SA reduced by 70% after increasing the volume of gel.
Another curve: OD value of elutropic protein
Fig. 2 shows SDS-PAGE Gel electrophoresis ofthe PMC-S
From left to right in the order:
a. 1. Marker, 2. PMC-SA1 produced by TGI, 3. PMC-SA1 produced by BL-21 , 4. PMC-SA1 produced byB834;
b. 1. Marker, 2. PMC-SA1 eluted by boric acid buffer solution with 0.1 M NaCl, 3. 20 PMC-SA1 eluted by boric acid buffer solution with 0.2 M NaCl, 4. PMC-SA1 eluted by boric acid buffer solution with 0.3 M NaCl.
Fig. 3. Shows the inhibition curve of the PMC-SA against MRSA (BAA42 )
Y-axis represents light absorption value; X-axis represents bacterial growth time 25 Control: control group; Amp: ampicillin sodium; OXA: oxacillin; la-wt: wild type colicin la; PMC-SA1: anti-staphylococcus aureus polypeptide;
PMC-AM: anti-diplococcus meningitides polypeptide.
DETAILED DESCRIPTION OFTHE INVENTION
Following examples are just used for explaining the invention rather than limiting the scope of the invention.
The experimental equipment and instruments used in présent invention as follows:
------U-Bacterial-stram-------------------------------------------------------------------------E. coli TGI engineering bacteria (AECOM, K. Jakes).
E. coli BL-21(DE3)> B834(DE3)> Nova Blue(DE3) and 618 engineering bacteria are ail purchased from Novagen company.
Staphylococcus aureus ATCC BAA-42 is purchased from ATCC (American Type Culture Collection).
Plasmid: pBHC-SAK pBHC-SA2> pBHC-SA3 pBHC-SA4. pBHC-SE, pBHC-PA, pBHC-PorAl (These plasmids are recorded in patents ZL200910092128.4 and ZL 200910157564.5, and preserved in the applicant’s laboratory. The applicant promised to offer them to the public for necessary vérification tests)
2. Main reagents and medicine
Yeast powder (OXIOD LP0021), peptone (OXIOD LP0042) as well asother chemical reagent are ail analytical reagent;
----------Dialysis-bag-Snake-Sk-in-Dialysis-Tubing-¢I1ieFeeΓintereept-moleeul·ar-weightT>,'-lΘ4^----Lot#KD32324);
Streptomycin Sulfate for injection (NCPC)
AMP ampicillin sodium for injection (Harbin pharmaceutical)
Anion exchange column gel (Pharmacia Biotech CM Sepharose Fast Flow LotNo.225016) .
LB Iiquid medium: Sodium chloride 1g, peptone 1g, and yeast 0.5g were added into a 250 ml flask with the addition of 100 ml water, dissolved and autoclaved at 120Π for 8min.
LB solid medium: lOOmlLB solid medium containing sodium chloride 0.5-1.5g, peptone 0.5-2g, yeast 0.3-1 g and agar 0.8-3g. The LB solid medium is used for plate 5 culture of single colony after strain recovery. Reagents were added into a 250 ml flask with the addition of 100 ml water, dissolved and autoclaved at 120C for 8min.
...........FB.-M9 complex medium: NaCl 6.0~6.7g/L, peptone 25.0g/L, yeast powder -----7.5g/L, glucose 0.6-2.Og/L, Na2HPO4-7H2O 6.8—18.3g'L, KH2PO4 3.0—4.3g/L,-NH4CI 1.0-1.4g/L, MgSO4 0.2-0.4g/L, CaCl20.01g/L, méthionine 0~40mg/L.
Improved FB-M9 complex medium: NaCl 6.0g/L, peptone 25.0g/L, yeast powder 7.5g/L, glucose 2.0g/L, Na2HPO4-7H2O 6.8g/L, KH2PO43.0g/L, NH4C1 l.Og/L, MgSO40.2g/L, CaCl20.01g/L, méthionine 0~40mg/Lo The méthionine is 40mg/L in the process with E.coli B834(DE3) as engineering bacteria.
3. Key Instrument
Bio-Rad Protein chromatography purification System C BioLogic Duo Flow, BioLogic Maximizer, BioLogic QuadTec UV-Vis Detector, BioLogic Econo Pump);
Ultrasonic Cell Disruptor (Soniprep 150), protein purification ion exchange column with 5cm diameter (Pharmacia Biotech XK50) /protein purification ion 20 exchange column with 11cm diameter (Shanghai Huamei);
Centrifuge (Beckman Coulter Avanti J-20XP, Beckman Coulter Avanti J-25);
----------Spcctrophotometer (Bio-Rad Smart Spect Plus spectrophotometer):------------------Automatic fermenter (Bioengineering AG LP351-42L);
High pressure homogenizer (Italian NiroSoavi NS1001L2K.SN 6564).
Statement: the biological materials adopted in this invention hâve been known before the application fïling date and hâve been also preserved in this applicant’s lab. The applicant promised to offer them to the public for necessary vérification tests in the twenty years since application filing date.
Example 1. The option experiment of engineering bacterial strains
Classic plasmid carried the colicin la and its immune protein gene (GenBank M13819) are from laboratory of Dr, Finkelstein. (Qiu XQ et al. An engineered multi domain bactericidal peptide as a model for targeted antibiotics against spécifie bacteria.
Nat Biotechnol, 2003 ; 21(12): 1480-1485). The classic plasmid weremodified into foliowing seven kinds of restructuring mutation plasmids in former researchs: pBHC-SAl v pBHC-SA2 > pBHC-SA3 pBHC-SA4 < pBHC-SE , pBHC-PA , ----pBHG-PorAE---------------------------------------------------10 Step 1. Transformation of competent cell
40pL Novagen pET System engineering bacteria BL-21(DE3)x B834(DE3)> Nova Blue(DE3)> 618 were respectively transformed with lOOng recombinant mutant plasmids pBHC-SAl, and then ice-incubated for 5 minutes, heat-shocked at 42°C for 30 seconds, kept in ice for 2minutes, added with 160μ1 SOC medium and 15 shake-cultivated at 220 rpm, 37°C for 1 hour and then coated (LB medium with 1% agar and 50ug/ml ampicillin, and cultured ovemight at 37°C). Single colonies are picked out and cultivated to obtain the seed strain, which is conserved at a low température.
Step2: Strain Recovery
------1—Preparing-reeovered-baeteria-soltttion----------------------------------------------The conserved strain was thawed at 4°C ; 1.5ml of the strain is transferred into 10ml LB medium (containing 50pg/ml of AMP) and cultivated at 220 rpm, 37°C for 5-8 25 hours.
2. Inoculation of single colony
The recovered bacteria solution was diluted 104 or 105 times; and lOul of the diluted bacteria solution was transferred on to LB solid medium plate (containing 50pg/ml of AMP) and coated on the plate. The plate was placed in a humid box and cultivated in incubator at 37°C for 10-12 hours till round single colonies hâve grown out on the surface of the medium.
Step 3. Enlargement culturing the single colonies (1) Single colonies with regular round shape and smooth edge were picked up from the plate and respectively added into -l-^ml-LB-mediumr-and-eultivated-at-^-Orpmy^V-C—for-é-Shours^-----------------------10 (2) Each 1.5ml LB bacteria solution was transferred into a 100ml LB medium, and cultivated at 220rpm, 37 °C for 5-8hours.
(3) Primary stage of enlargement culturing: the 100ml of bacteria solution from the last step was added into 700ml of improved FB-M9 complex medium and cultivated at 220 15 rpm, 37°C for 5-8 hours.
(4) Secondary stage of enlargement culturing: 700ml of bacteria solution from the primary stage is added into 6x700ml of the improved FB-M9 complex medium and cultivated at 220rpm, 37°C for 5-8hours.
(5) Third stage of enlargement culturing: 6*700ml of bacteria solution from the -seeondar-y-stagc—was-added-into-20f^of-the-improved-FB-M9-eomplex-medium-and----- cultivated in a fermenter with stirring rate of 220rpm and maximum oxygen flow volume, 37°C for 3-5 hours.
(6) Fermentation of engineered bacteria and induced expression of protein: 20L of bacteria solution from the third stage of enlargement culturing was added into 200L of improved FB-M9 complex medium and cultivated in a fermenter for induced expression of protein with stirring rate of 220rpm and maximum oxygen flow volume, at 30°C for 2~4hours; 42°C for 0.5 hours; and 37°Cfor l~2hours, note that IPTG is added at 42°Cwith a final concentration of 0.5mM.
Step 4, Collecting bacteria by centrifugation
6000 g fermentation liquor obtained from step 3 was centrifuged at 4°C for 20min. .......The precipitate was collected and added into 50mM boric acid buffer (pH9.0) for -----resuspend—of—the—bacteria^-Note-4—the boric acid buffer has 2mM PMSF (Phenylmethylsulfonyl fluoride serine protease inhibitor). Ail conséquent steps after 10 bacteria resuspend was conducted at 4“C.
Step5.Cells fragmentation
After suspension in pH9.0 boric acid buffer completely, the bacteria cells was fragmented by a High Pressure Homogenizer at 500-600 bar for 7 times, with intervals 15 of 3-5 minutes.
Step6. Précipitation of the bacteria DNA
The fragmented bacteria solution was centrifuged at 55000 g, 4°C for 40 min. The supematant was added with streptomycin sulfate (16 bottles of 1 million unit 20 streptomycin sulfate were added into every 200ml liquid supematant), and stirred for 1 h with a magnetic stirrer.
Step7. Dialysis
The bacteria solution from the step 6 was centrifuged at 55000g, 4D for 20min. The supematant was placed into a dialysis bag and dialyzed for 8—12 hours in boric acid buffer, which was changed once every 4 hours.
Step8. Purifying the protein medicine and obtaining antibacterial-engineered polypeptide
The dialyzed bacteria solution was centrifuged at 55000g, 4 °C for 20min. The supematant was measured the protein concentration in unit volume and placed into a
Bunsen beaker for conducting protein purification by ion exchange method. The .......supematant with known protein concentration was uploaded onto a CM ion exchange..... ----------column.-The-sample-loading-and-its-ratio-with-the-CM-iron-gel-particular-arc-aGGording----to the Product Manuals of CM ion exchange column. After being washed completely the CM ion exchange column was eluted with 50mM boric acid buffer containing 0.3M
NaCl to obtain the novel antibacterial-engineered polypeptide.
The résulte are shown as table 1, the expressing efficiency of PMC-SAby E.coli B834 (DE3) is the highest.
Table 1. Expressing efficiency of different bacterial strain (Average unit production^Gross production of extracted PMC-SA1/ volume of bacterial liquid)
Engineering strain | TGI BL-21 618 NavaBlue B834 |
Average unit production (mg/L) | 0.8 10 5.8 8.1 24.4 |
The same operation was conducted on the other six restructuring mutation plasmids, the -20---resulte-appeared^similar-trend-as-the-result-listed-in^able-lvonmelyriii-eontrast-to-otherengineering bacteria, E. coli B834 (DE3) showed the highest expressing efficiency on ail seven restructuring mutation plasmids.
The operation of heat shock as following adopted to inducing expression of protein in this embodiment was different from that in prior arts: After transferring the seed 25 bacteria liquid into the tank, cultured the bacteria at an initial température 30°Cfor 2 hours, when OD value had reached 0.4-0.6, conducted the heat shock at 42°C for 30 minutes, then when the température low down to 37°C, cultured the bacteria again for
1.5 to 2 hours again. At this stage the OD value of bacteria liquid can reach to 1-3 or even more, and can be conducted collection. During this process, 0.5mM IPTG was added to induce expression of pET engineering bacteria.
Before proposing présent method, the usual process for preparing the recombinant ......peptides was as following:..........................................
lOOng of the mutant plasmids was ice-incubated with 40ul competent cell of BL-21 engineered bacteria for 5 minutes, heat-shocked at 42°C for 30 seconds, ice-incubated for 2 minutes, added with 160ul of SOC medium, shake-cultivated at 220 rpm, 37°C for Ihour and then coated plate (LB medium with 1% agar and 50ug/ml ampicillin, and cultured ovemight at 37 °C). Single colonies were picked out for enlargement culturing. Emargement culturing: 8-10L FB medium, 250rpm, at 37°C for 3-4 hours; was added with 1PTQ 250rpm, at 28°C grew for 4 hours again; conducted centrifugation to precipitate bacteria at 4°C, 6000g, 20 minutes. The precipitated bacteria was added with 80-100ml 50mM boric acid buffer (pH9.0, 2mM EDTA) kept at 4°C to suspend, then added with 50ug PMSF and broken by ultra sonication (4°C, 400 w, 1 minutes, repeat 4 to 5 times with intermittent 2-3 minutes for keeping the température of the liquid).
Then the broken bacteria was conducted high-speed centrifugation (4°C, 75000g, 90minutes), the supematant was added with 5 million units streptomycin sulfate to ------prGGipitate-DNA-(4-Cstirred-for-l-hour-)rand-lOOOOg^4-Cy-for-10minutes_centriftigationr The supematant was put into dialysis bag with the molecular weight 15000 on 4°C, and dialyzed by 10L 50 mM boric acid buffer ovemight, then conducted centrifugation at
4°C, 10000g, forlOminutes once again. The supematant was loaded on CM ion exchange column, after being flushed completely, eluted by 0.3M NaCl + 50mM boric acid buffer, the new antibiotics can be obtained.
Example 2 Improving medium
The classic FB medium for colicin la préparation (Qiu XQ et al. An engineered multi domain bactericidal peptide as a model for targeted antibiotics against spécifie bacteria.
Nat Biotechnol, 2003; 21(12): 1480-1485 /Karen Jakes, Charles Abrams, Alan
Finkelstein, et al. Alteration of the pH-dependent Ion Selectivity of the Colicin El
Channel by Site-directed Mutagenesis.JBC, 1990; 265(12): 6984-6991) has components as follows: peptone 25.0g/L, yeast powder 7.5g/L, NaCl 6.0g/L and ----gluGose-kOg/L.-----------------------------------------------------------------10 In this invention, we adopted FB medium without glucose, the components of which as follows: peptone 25.0g/L, yeast powder 7.5g/L and NaCl 6.0g/L. And the FB medium without glucose was configured with M9 medium at a spécial volume proportion to obtain the FB-M9 compound medium.
The mother liquor of M9 medium is 5*M9 and has components as follows: :
Na2HPO4-7H2O 64.0g/L, KH2PO4 15.0g/L, NH4C1 5.0g/L, NaCl 2.5g/L, MgSO4 1.5g/L, CaCl2 0.05g/L, and 2% glucose.
A preliminary attempt of the compound medium:
FB-M9: volume ratio between FB:M9 was 7:10, the components as follows: NaCl
6.7g/L , peptone 25.0g/L , yeast powder 7.5g/L , Na2HPO4-7H2O18.3g/L ,
-----]Œ-2BQ44I3g/-L,—NH4C1-L4g/-L,—MgSC^OAg/L·,—CaCl2OτO-l-gZL·and-glucose-0î6g/-L·---This invention adopted this formula for bacteria fermentation. The process was as step3 in Example 1. The resuit shows in table2, wet bacteria weight got from per liter culturei solution is significantly higher than that done through FB medium. The collected;
protein production is significantly improved with average production up to 30 mg/L.ï
Table 2 contrast of target protein production from test medium (PMC - SA1 / BL - 21 engineering bacteria)
Fermenting in BF medium | Fermentingin FB-M9 (7: 10) medium | |||
Bacterial weight (g) contents(mg) | Protein | Bacterial weight (g) | Protein contents (mg) | |
1 | 255.07 | 280.8 | 349.82 | 847.82 |
......2 | ..... 246.3 .......... | .....519.94 | ......343.47 | 643.71 ......... |
3 | 302.28 | 461.965 | 366 | 779.3 |
4 | 276.67 | 465.179 | 388.44 | 946.34 |
A VG | 270.8 | 431.971 | 361.9325 | 804.2925 |
The final improved FB-M9 medium was obtained by further researchs and repeated comparison in this invention. The production rate of the target protein can reach 34 mg/L as Table 3 shows, in the same fermentation conditions as example 1.
The components of the improved FB-M9 medium as follows: NaCl 6.0g/L, peptone
25.0g/L, yeast powder 7.5g/L, glucose 2.0g/L, Na2HPO4-7H2O6.8g/L, KH2PO43.0g/L,
NH4C1 l.Og/L, MgSO40.2g/L and CaCl20.01g/L. As the méthionine was required in the growth of B834 engineering bacterium, in the process of B834 as engineering bacteria the méthionine (40 mg/L) is added into the final improved FB-M9 medium.
Iable 3 c.ompansQn^Q.f im.p.roveri FR - M9 medi.um w.i.th—o.th,er medi.um on
----produeti-vit-y----
Engineering strains and the medium | BL-21 | B834 | ||||
FB | FB-M9 (7: 10) | Improved FB-M9 | FB | FB-M9 (7: 10) | Improved FB-M9 | |
Average unit production (mg/L) | 10 | 24 | 25 | 22.3 | 30 | 34 |
Example 3. Optimizing conditions for purifying protein
The basic structure of recombinant polypeptide (PMC- SAl PMC-SA2 -, PMC -SA3, PMC -SA4> PMC -SE, PMC -PA, PMC-AM) prepared in this invention is Colicin la.
The isoelectric point of colicin la is about 9.15, therefore the classic purification adopted is Ion Exchange Chromatography (Qiu XQ et al. An engineered multidomain bactericidal peptide as a model for targeted antibiotics against spécifie ..........bacteria. Nat Biotechnol, 2003; 21(12): 1480-1485).........................
The principle is: In PH9.0 boric acid buffer system, the majority of PMC-SA molécules exist as positive charge ions. When the CM gel particles with négative charge go through the chromatographie column, the recombinant protein molécules with positive charge was hung on the CM gel particles due to the electric charges attraction, while the other miscellaneous protein was rushed out of the gel column.
In this example, the other steps were as that in example 1, but after the miscellaneous protein was rushed out completely, using boric acid buffer of 0.1 to 0.3M NaCl gradiently to elute the gel column.
Owning to Na+ ions having stronger positive property than the recombinant protein 20 molécules, the recombinant protein was replaced from CM gel particles by Na+ ion.
There are two variables to be manipulated in the process of ion exchange and -----purification—for— a-better—protein—;yield: ©NaCl—with different concentration—within----0.05-IM can be chosen respectively to elute protein molécules with different positive charge mounted on CM gel particles Cg)The amount of CM gel particles adopted can be 25 optimized: iïi the environment with certain ionic strength, the amount of protein carried by every CM gel particles is relativeiy constant. The volume of gel column is indispensable to be enlarged in order to increase the amount of protein carried by gel column.
CM Sepharose Fast Flow is anion exchange column gel produced by GE company. According to the manual, every 100 ml gel can combine with 9mM cation. The actual usable combination capacity varies with the nature of sample in the process of dynamic combination, and molecular weight is inversely proportional with combined capacity.
Its standard sample that has équivalent molecular weight with the recombinant peptides manufactured in this invention is Bovine COHb-(Mr69kD), which has theoretically ...... dynamic combined capacity 3 Omg/ml. Namely, with 100 ml CM Sepharose Fast Flow ------gluc to rctncve recombinant protein molécules, the thcoretically higlicst rccovery rate is about 300 mg (0.004mM). But according to its manual operation, the actual dynamic 10 combination capacity of recombinant protein molécules to CM gel particles reached only 3 mg/ml, just reached 10% of theoretical combined capacity.
In the experiment, we found that in the latter half process of washing out the miscellaneous protein, conductance curve will raise a small peak (as shown in figure 1 15 a). According to this phenomenon, we speculate that when there is a large amount of recombinant protein in the sample, due to the limited capacity of CM gel particles with target protein, only a little part of the recombinant protein molécules can be recovered. The recombinant protein without being mounted on the CM gel particles has to be flushed out gel column together with miscellaneous protein. As the recombinant protein 20 is positively charged, a short rising peak appears in the conductance curve.
In an optimized example of this invention: in ordcr to reduce the loss of recombinant--= proteins, we reduced loading amount of sample to 1/3 of the manual régulation, and increased the volume of gel from 150 ml to 600 ml, namely the protein amount in the 25 supernatant fluid: gel particle volume=2.5mg/ml. The loss of the recombinant protein decreased in the process of elution. The experimental data showed that the recovery rate of recombinant proteins was increased 3.5 times; the results shown in figure lb.
In addition, we set the gradient concentration of NaCl as 0.1M-0.2M-0.3 M in the boric acid buffer used in elution, and 0.2M showed the highest eluting efficiency and protein purity, as shown in figure 2b.
Example 4. Detecting protein purity and activity
Step 1. SDS-PAGE eiectrophoresis
........The fusion protein samplcs obtained by optimized conditions of example 4 were ------conducted-SlDS-PAGE-eleGtrophoresiii-and-silver-nitrate-dyeing—As shown in figure 2,----there is a clear protein-imprinting stripe at the point of about 70kD relative molecular weight, namely PMC - S Al manufactured in this invention in the eiectrophoresis map a the map b shows the protein has eliminated mixed zone through the improved gradient elution in example 4 and the purity is improved. The rest six kinds of recombinant proteins manufactured through the optimized method of this invention hâve also showed similar improved purification.
Step 2. Detecting the antibacterial activity
With the recombinant protein PMC - SA1 and PMC-AM that produced by the improved manufacturing method in the example 1, 2, 3, we conduct the following antibacterial activity test.
The Methicillin-resistant staphylococcus aureus (MRSA, ATCC BAA-42) bacteria -----liquid—l-0ul—(-10-efu/ml-)—was—inoeulate—into-t-lO—ml-BM—medium and—added—with---antimicrobial agents. According to the antimicrobial agents we set six parallel groups: ampicillin sodium 2ug/ml, oxazocilline 4ug/ml, wild type colicin la, PMC-SA and 25 Ph-NM (4ug/ml), and blank control group. Culturing at 37°C, 210rpm, and testing optical densîty value per hour (595 nm), drawing the bacteriostasis curve, as shown in figure 3.
The bacteriostatic curve shows that the recombinant proteins produced by improved methods of this invention hâve good antibacterial activity
- | |
19 |
Claims (11)
1. A method for highly expressing recombinant protein of engineering bacteria, wherein the end with hydrophilicity of the recombinant protein is colicin polypeptide and the other end with hydrophobie nature is polypeptide of target moiety which is capable of
5 binding target, the method comprising:
..........(1) transfecting recombinant plasmid of expressing the recombinant protein into E.coli ------engineering-baeteria-with-pET-system-to-obtain-positive-monoelonal-eolonies^----------- (2) producing seed bacteria solution of the positive monoclonal colonies, and inducing 10 protein expression and enlargement culturing of the seed bacteria solution; the supematant of the enlargement cultured solution contains expressed recombinant protein, (3) extracting and purifying the recombinant protein from the supematant, wherein the E.coli engineering bacteria with pET system is E.coliB834 (DE3).
2. According to the method of claim 1, enlargement culturing medium used for said enlargement culturing of the seed bacteria solution has water as solvent and comprises following components: NaCl 6.0~6.7g/L, peptone 25.0g/L, yeast powder 7.5g/L, glucose 0.6~2.0g/L, Na2HPO4-7H2O 6.8~18.
3g/L, KH2PO4 3.0~4.3g/L, NH4C1
20 1.0-1.4g/L, MgSO4 0.2~0.4g/L, CaCl20.01 g/L, méthionine 0~40mg/L.
-----3. According to the method of claim 2, the enlargement culturing medium has water as solvent and comprises following components: NaCl 6.0g/L, peptone 25.0g/L, yeast powder 7.5g/L, glucose 2.0g/L, Na2HPO4-7H2O 6.8g/L, KH2PO4 3.0g/L, NH4C1 l.Og/L, 25 MgSO4 0.2g/L, CaCl20.01g/L, méthionine 0~40mg/L.
4. According to any method of claim 1-3, wherein said enlargement culturing of the seed bacteria solution comprises following steps: the seed bacteria liquid was added into a container and started growth for 2 to 3 hours at 30°C, when the OD value reached 0.4-0.6, the seed bacteria solution was conducted heat shock at 42“C for 30 minutes, and then cooled down to 37 °Cand kept growth for 1.5 to 2 hours before being collected.
5. According to the method of claim 4, in conducting heat shocks, the IPTG with final ......concentration 0.5mmol/L was added into said enlargement culturing medium.............
6. According to the method of claim 1, said extracting and purifying the recombinant
10 protein from the supematant was by CM ion exchange column, and the loading quantity of the supematant samples dépends on the ratio value which is 2.5mg/ml between the weight of the recombinant protein in the supematant and the volume of Gel particles used in the CM ion exchange column.
15
7. According to the method of claim 6, the eluent solution used for said extracting and purifying in CM ion exchange column is boric acid buffer solution with 0.2mol/LNaCl.
8. According to the method of claim 1, the recombinant plasmid of expressing the recombinant protein is selected from the group consisted of pBHC-SAl > pBHC-SA2,
20 pBHC-SA3 pBHC-SA4> pBHC-SE, pBHC-PAand pBHC-PorAl.
-----
9.—The application of any method of claims 1-8 in preparing the recombinant peptides PMC-SA1, PMC-SA2, PMC -SA3, PMC-SA4, PMC-SE, PMC-PA or PMC-AM.
25
10. A medium used for E.coli engineering bacteria with pET system, the medium has water as solvent and comprises following components: NaCl 6.0-6.7g/L, peptone 25.0g/L, yeast powder 7.5g/L, glucose 0.6~2.0g/L, Νη2ΗΡΟ4·7Η2Ο 6.8~18.3g/L, KH2PO4 3.0 ~ 4.3g/L, NH4CI 1.0-1.4g/L, MgSO4 0.2~0.4g/L, CaCl20.01g/L, méthionine 0~40mg/L.
11. According to the medium of claim 10, wherein said E.coli engineering bacteria with pET system is E.coli B834 (DE3), and the medium has water as solvent and comprises
5 following components: NaCi 6.0g/L, peptone 25.0g/L, yeast powder 7.5g/L, glucose 2.0g/L, Na2HPO4-7H2O 6.8g/L, KH2PO4 3.0g/L, NH4C1 l.Og/L, MgSO40.2g/L, CaCl2 ......0.01 g/L, méthionine 0~40mg/L.......................................................................
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110380864.7 | 2011-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA19038A true OA19038A (en) | 2019-12-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012342993B2 (en) | Method for highly expressing recombinant protein of engineering bacteria and use thereof | |
Kefala et al. | Structures of the OmpF porin crystallized in the presence of foscholine‐12 | |
Korneli et al. | High yield production of extracellular recombinant levansucrase by Bacillus megaterium | |
Chen et al. | Enhanced production of polysialic acid by metabolic engineering of Escherichia coli | |
KR100313135B1 (en) | Expression Vectors Comprising a Gene Encoding OmpC Derived from E.coli as Cell Surface Anchoring Motif | |
TWI541350B (en) | A Method for Highly Efficient Expression of Recombinant Protein from Engineering Bacteria and Its Application | |
TWI751154B (en) | A preparation method of recombinant human granulocyte colony stimulating factor | |
CN108333152B (en) | Biotinylated antibody sensor based on gene recombinant phycocyanin MAC and graphene oxide quantum dots and preparation method thereof | |
OA19038A (en) | Method for highly expressing recombinant protein of engineering bacteria and use thereof. | |
CN110468143B (en) | Preparation method and application of antibacterial peptide NZX | |
RU2524133C2 (en) | Escherichia coli BACTERIA STRAIN - PRODUCER OF RECOMBINANT FLAGELLIN | |
CN117106808A (en) | Engineering yeast strain for high-yield human recombinant collagen and application thereof | |
Xu et al. | Expression of human β-defensin-2 with multiple joined genes in Escherichia coli | |
WO2019114534A1 (en) | Fermentation production process for protein drugs | |
NZ625595B2 (en) | Method for highly expressing recombinant protein in recombinant bacteria and use thereof | |
US10337018B1 (en) | Asparaginase mutant with efficient expression, activity and stability | |
CN103861101B (en) | A kind of Novel chimeric flagellin adjuvant of helicobacter pylori polyepitope vaccines | |
RU2537006C2 (en) | RECOMBINANT PLASMID pPA-OPRFI DNA CODING HYBRID RECOMBINANT F-I PROTEIN OF Pseudomonas aeruginosa OUTER MEMBRANE, STRAIN Escherichia coli PA-OPRFI PRODUCING HYBRID RECOMBINANT F-I PROTEIN OF Pseudomonas aeruginosa OUTER MEMBRANE AND METHOD FOR PRODUCING HYBRID RECOMBINANT F-I PROTEIN OF Pseudomonas aeruginosa OUTER MEMBRANE | |
Zhang et al. | Elongation Factor Ts ofChlamydia trachomatis: Structure of the Gene and Properties of the Protein | |
Duan et al. | Intein-mediated protein trans-splicing of the recombinant streptavidin on magnetosomes | |
CN117253547A (en) | Controllable protein recruitment system based on artificial protein cage and construction method thereof | |
Lv et al. | Indipendent and tandem expression of a novel antimicrobial peptides plectasin in Escherichia coli | |
Magkakis | LMCA1 as prototype system for the study of Ca2+ pumps in nanodisks | |
Sadri et al. | Enhanced Expression and Bioactivity Assessment of Recombinant SUMO‐Protease‐1 in E. coli BL21 (DE3) via Cleavage of His6‐SMT3‐SDF‐1 Fusion Protein | |
CN114574512A (en) | Preparation of cell-penetrating peptide-target protein compound and method for efficiently introducing cell-penetrating peptide-target protein compound into streptomyces living cells |